[go: up one dir, main page]

PE20211454A1 - Derivados de imidazopiridina y su uso como medicamento - Google Patents

Derivados de imidazopiridina y su uso como medicamento

Info

Publication number
PE20211454A1
PE20211454A1 PE2020000681A PE2020000681A PE20211454A1 PE 20211454 A1 PE20211454 A1 PE 20211454A1 PE 2020000681 A PE2020000681 A PE 2020000681A PE 2020000681 A PE2020000681 A PE 2020000681A PE 20211454 A1 PE20211454 A1 PE 20211454A1
Authority
PE
Peru
Prior art keywords
medicinal product
methyl
compound
imidazopyridine derivatives
imidazopyridine
Prior art date
Application number
PE2020000681A
Other languages
English (en)
Inventor
Riccardo Giovannini
Angelo Ceci
Georg Dahmann
Cornelia Dorner-Ciossek
Lothar Kussmaul
Roland Pfau
Dieter Wiedenmayer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20211454A1 publication Critical patent/PE20211454A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Referido a un compuesto de formula A, en donde R1 representa fenilo que es opcionalmente sustituido con 1 a 3 sustituyentes seleccionados entre F, Cl, metilo, etilo, entre otros; R2 es H, metilo; y R3 es H o F; o una sal farmaceuticamente aceptable. Estos compuestos son derivados de imidazopiridina, y tiene propiedad de modulacion alosterica negativa de NR2B. Tambien se refiere a su proceso de preparacion de dicho compuesto, composiciones farmaceuticas que los contienen, y su uso en tratamientos, particularmente, en el tratamiento o prevencion de trastorno bipolar I: sintomas de depresion, hipomaniacos, maniacos, entre otros.
PE2020000681A 2017-12-08 2018-12-06 Derivados de imidazopiridina y su uso como medicamento PE20211454A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17206152 2017-12-08
PCT/EP2018/083728 WO2019110703A1 (en) 2017-12-08 2018-12-06 Imidazopyridine derivatives and the use thereof as medicament

Publications (1)

Publication Number Publication Date
PE20211454A1 true PE20211454A1 (es) 2021-08-05

Family

ID=60629568

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000681A PE20211454A1 (es) 2017-12-08 2018-12-06 Derivados de imidazopiridina y su uso como medicamento

Country Status (34)

Country Link
US (1) US10849907B2 (es)
EP (1) EP3720855B1 (es)
JP (1) JP6941235B2 (es)
KR (1) KR102728343B1 (es)
CN (1) CN111344291B (es)
AR (1) AR113923A1 (es)
AU (1) AU2018379438B2 (es)
BR (1) BR112020008583A2 (es)
CA (1) CA3083331A1 (es)
CL (1) CL2020001402A1 (es)
CO (1) CO2020006648A2 (es)
CY (1) CY1124744T1 (es)
DK (1) DK3720855T3 (es)
EA (1) EA202091139A1 (es)
ES (1) ES2897050T3 (es)
HR (1) HRP20211726T1 (es)
HU (1) HUE056667T2 (es)
IL (1) IL274868B2 (es)
LT (1) LT3720855T (es)
MA (1) MA51020B1 (es)
MX (1) MX2020005869A (es)
MY (1) MY203080A (es)
NZ (1) NZ763704A (es)
PE (1) PE20211454A1 (es)
PH (1) PH12020550785A1 (es)
PL (1) PL3720855T3 (es)
PT (1) PT3720855T (es)
RS (1) RS62517B1 (es)
SA (1) SA520412155B1 (es)
SG (1) SG11202005138TA (es)
SI (1) SI3720855T1 (es)
TW (1) TWI809014B (es)
UA (1) UA126247C2 (es)
WO (1) WO2019110703A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020245136A1 (en) * 2019-06-04 2020-12-10 Boehringer Ingelheim International Gmbh Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders
US12398143B2 (en) 2019-06-04 2025-08-26 Boehringer Ingelheim International Gmbh Imidazopyrazine derivatives and the use thereof as medicament

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495561B2 (en) * 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
TWI225488B (en) * 1999-12-21 2004-12-21 Janssen Pharmaceutica Nv Derivatives of homopiperidinyl substituted benzimidazole analogues
SK287726B6 (en) 2001-07-24 2011-07-06 Richter Gedeon Vegyeszet Carboxylic acid amide derivatives, their preparation, pharmaceutical compositions containing them and process for preparing pharmaceutical compositions
CA2567935C (en) * 2004-05-27 2009-10-27 Pfizer Limited Aminopyridine derivatives as selective dopamine d3 agonists
TW200831084A (en) * 2006-11-21 2008-08-01 Genelabs Tech Inc Anti-viral compounds
WO2010088408A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor antagonists for the treatment of neurological conditions
NZ705144A (en) 2012-10-18 2018-09-28 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
CN106255679B (zh) 2014-02-27 2019-09-06 默克专利有限公司 用作nav通道抑制剂的杂环化合物及其用途
AU2015271719A1 (en) * 2014-06-04 2016-12-01 Rugen Holdings (Cayman) Limited Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
WO2016044323A1 (en) * 2014-09-15 2016-03-24 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists

Also Published As

Publication number Publication date
IL274868A (en) 2020-07-30
DK3720855T3 (da) 2021-11-08
CN111344291B (zh) 2023-05-05
AU2018379438A1 (en) 2020-05-07
SA520412155B1 (ar) 2022-06-05
JP2021505584A (ja) 2021-02-18
IL274868B2 (en) 2024-06-01
IL274868B1 (en) 2024-02-01
PH12020550785A1 (en) 2021-04-12
MY203080A (en) 2024-06-07
UA126247C2 (uk) 2022-09-07
CO2020006648A2 (es) 2020-06-09
MA51020A (fr) 2021-05-26
RS62517B1 (sr) 2021-11-30
HUE056667T2 (hu) 2022-02-28
CL2020001402A1 (es) 2020-09-21
MA51020B1 (fr) 2021-10-29
TW201936198A (zh) 2019-09-16
CN111344291A (zh) 2020-06-26
EP3720855A1 (en) 2020-10-14
JP6941235B2 (ja) 2021-09-29
TWI809014B (zh) 2023-07-21
US20190175605A1 (en) 2019-06-13
EP3720855B1 (en) 2021-08-25
LT3720855T (lt) 2021-11-10
US10849907B2 (en) 2020-12-01
KR102728343B1 (ko) 2024-11-11
SI3720855T1 (sl) 2021-12-31
CY1124744T1 (el) 2022-07-22
MX2020005869A (es) 2020-09-09
AU2018379438B2 (en) 2022-08-18
BR112020008583A2 (pt) 2020-10-20
CA3083331A1 (en) 2019-06-13
ES2897050T3 (es) 2022-02-28
PT3720855T (pt) 2021-11-03
WO2019110703A1 (en) 2019-06-13
SG11202005138TA (en) 2020-06-29
EA202091139A1 (ru) 2020-11-23
KR20200097301A (ko) 2020-08-18
NZ763704A (en) 2026-01-30
HRP20211726T1 (hr) 2022-02-18
AR113923A1 (es) 2020-07-01
PL3720855T3 (pl) 2022-01-24

Similar Documents

Publication Publication Date Title
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2023011675A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
AR100006A1 (es) Derivados de tubulisina
EA201892734A1 (ru) ПРОИЗВОДНЫЕ АЗАБЕНЗИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ pI3K BETA
PE20180232A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
UY36257A (es) “compuestos de imidazopiridazina”.
PE20142186A1 (es) Derivados biciclicos de pirazinona
PE20200341A1 (es) Composiciones y compuestos terapeuticos y metodos para utilizarlos
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
CU20160148A7 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
EA201600323A1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento
DOP2022000073A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR077395A1 (es) Derivados de 2- 1,2 -bencisoxazol-3-il ) bencilamina